TITAN PHARMACEUTICALS INC
10-Q, EX-27.1, 2000-11-14
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: TITAN PHARMACEUTICALS INC, 10-Q, EX-10.34, 2000-11-14
Next: HAIN CELESTIAL GROUP INC, 10-Q, 2000-11-14



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS INCLUDED IN THE COMPANY'S FORM 10-Q
FOR THE PERIOD ENDED SEPTEMBER 30, 2000, AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                           6,334
<SECURITIES>                                    73,463
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                80,083
<PP&E>                                             878
<DEPRECIATION>                                   (351)
<TOTAL-ASSETS>                                  80,626
<CURRENT-LIABILITIES>                            2,975
<BONDS>                                              0
                                0
                                          0
<COMMON>                                       150,123
<OTHER-SE>                                    (73,713)
<TOTAL-LIABILITY-AND-EQUITY>                    80,626
<SALES>                                              0
<TOTAL-REVENUES>                                 1,311
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                11,887
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                               (14,782)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (14,782)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (14,782)
<EPS-BASIC>                                     (0.59)
<EPS-DILUTED>                                   (0.59)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission